Meet the Proteona team at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, USA
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona will be at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco from the 13th to the 16th January, 2020.
The annual event is the largest symposium for healthcare investment, attracting industry players, startups, and investors. We are excited to be there to discuss the impact of single cell multi-omics on the future of precision medicine. See you there!
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).